Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic Molecular Alterations of <i>TP53</i>, <i>SIRT-1</i>, and miR-34a Expression in Atrial Fibrillation: A Prospective Exploratory Biomarker Study.

International journal of molecular sciences·2026
Same author

Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?

International journal of molecular sciences·2026
Same author

A Long-Term Prospective Evaluation of the Predictive Value of Molecular Markers in Serum and Cerebrospinal Fluid in Patients in the Early Stage of Multiple Sclerosis.

International journal of molecular sciences·2026
Same author

CHI3L1 Expression in Neutrophils and Plasma of Multiple Sclerosis Patients: Implications for Pathogenesis and a Potential Biomarker.

International journal of molecular sciences·2026
Same author

Cytotoxicity and Genotoxicity of Resin-Based Dental Composites Modified with Quaternary Ammonium Salts.

Journal of functional biomaterials·2025
Same author

Distinct local brain atrophy pattern in clinically stable multiple sclerosis patients during the peri-pregnancy period: A follow-up study.

Neurologia i neurochirurgia polska·2025

Related Experiment Video

Updated: May 14, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Opioid Signaling in Multiple Sclerosis: Emerging Targets for Repair.

Renata Perlikowska1, Małgorzata Domowicz2, Agnieszka Śliwińska1

  • 1Department of Nucleic Acid Biochemistry, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland.

International Journal of Molecular Sciences
|May 13, 2026
PubMed
Summary
This summary is machine-generated.

Opioid signaling shows promise for multiple sclerosis (MS) by potentially reducing inflammation, aiding myelin repair, and protecting nerves. Further research is needed to explore its therapeutic benefits beyond current treatments.

Keywords:
immunomodulationmultiple sclerosisneuroprotectionopioid signalingremyelination

More Related Videos

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Related Experiment Videos

Last Updated: May 14, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Area of Science:

  • Neuroimmunology
  • Neurodegenerative Diseases

Background:

  • Multiple sclerosis (MS) is a chronic CNS disorder involving inflammation, demyelination, and neurodegeneration.
  • Current MS therapies primarily target inflammation, with limited effects on neurodegeneration and potential safety concerns.

Purpose of the Study:

  • To explore the potential of opioid signaling as a novel therapeutic avenue for MS.
  • To investigate opioid signaling's immunomodulatory, remyelinating, and neuroprotective effects in MS.

Main Methods:

  • Review of emerging preclinical data on opioid signaling in MS.
  • Analysis of evidence regarding opioid-mediated interventions and their effects on inflammatory activity, demyelination, and neuronal survival.

Main Results:

  • Opioid signaling demonstrates potential for immunomodulation, remyelination, and neuroprotection in MS.
  • Evidence suggests opioid-mediated interventions can reduce inflammation, attenuate demyelination, and enhance neuronal survival.
  • Preclinical findings provide a rationale for investigating the opioid system in MS therapy.

Conclusions:

  • Opioid signaling represents an underexplored therapeutic pathway for multiple sclerosis.
  • Opioid-mediated interventions show promise as adjunctive or novel strategies for MS treatment.
  • Further investigation is warranted to validate the therapeutic potential of the opioid system in MS.